Irrigation system

A gravity irrigation system includes a distribution piping having apertures to distribute water to a field, and a valve located upstream of the distribution piping. The valve limits a pressure of the water being delivered to the distribution piping. The system also includes a sump to receive the water at a lowest elevation of the field, a depth sensor disposed within the sump, and a return pump disposed at least partially within the sump to move the water to an elevated portion of the field. The system also includes a motor to drive the return pump, and a power source coupled to a variable frequency drive that powers the motor and controls a motor speed proportionately to an indication of the depth sensor. The system also includes a transfer piping to bring the water from the return pump to a check valve and to the distribution piping

Systems And Methods For Performing Geo-User Content Provision Experiments

Systems, methods, and computer-readable storage media that may be used to conduct geo-user advertising experiments. One method includes determining a set of content items and filtering an activity log based on one or more characteristics of the set of content items to determine a subset of users. The method further includes retrieving geo-based data from the subset of users over a first timeframe. The method further includes designating one or more geographic regions associated with the subset of users as a treatment group and one or more geographic regions associated with the subset of users as a control group. The method further includes modifying a spend level associated with the treatment group and retrieving geo-based data over a second timeframe. The method further includes calculating an impact of the modification of the spend level and generating graphical interface data for presentation to a device of a content provider

Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?

LARGE is a glycosyltransferase involved in glycosylation of α-dystroglycan (α-DG). Absence of this protein in the LARGEmyd mouse results in α-DG hypoglycosylation, and is associated with central nervous system abnormalities and progressive muscular dystrophy. Up-regulation of LARGE has previously been proposed as a therapy for the secondary dystroglycanopathies: overexpression in cells compensates for defects in multiple dystroglycanopathy genes. Counterintuitively, LARGE overexpression in an FKRP-deficient mouse exacerbates pathology, suggesting that modulation of α-DG glycosylation requires further investigation. Here we demonstrate that transgenic expression of human LARGE (LARGE-LV5) in the LARGEmyd mouse restores α-DG glycosylation (with marked hyperglycosylation in muscle) and that this corrects both the muscle pathology and brain architecture. By quantitative analyses of LARGE transcripts we also here show that levels of transgenic and endogenous LARGE in the brains of transgenic animals are comparable, but that the transgene is markedly overexpressed in heart and particularly skeletal muscle (20–100 fold over endogenous). Our data suggest LARGE overexpression may only be deleterious under a forced regenerative context, such as that resulting from a reduction in FKRP: in the absence of such a defect we show that systemic expression of LARGE can indeed act therapeutically, and that even dramatic LARGE overexpression is well-tolerated in heart and skeletal muscle. Moreover, correction of LARGEmyd brain pathology with only moderate, near-physiological LARGE expression suggests a generous therapeutic window

Lewy Body Dementia Association\u27s Research Centers of Excellence Program: Inaugural Meeting Proceedings.

The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator\u27s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson\u27s disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics

The Politics of Social Inclusion: Bridging Knowledge and Policies Towards Social Change

This volume looks at concepts and processes of social exclusion and social inclusion. It traces a number of discourses, all of them routed in a relational power analysis, examining them in the context of the UN Agenda for Sustainable Development 2030 with its commitment to "leave no one behind." The book combines analysis that is fundamentally critical of the rhetoric of social inclusion in academic and UN discourse with narratives of social exclusion processes and social inclusion contestation, based on ethnographic field research findings in La Paz, Kingston, Port-au-Prince, Kampala, Beijing, Chongqing, Mumbai, Delhi, and villages in Northern India. As a result, it contributes to revealing the politics of social inclusion, offering policy proposals towards overcoming exclusions.Comparative Research Programme on Poverty (CROP) at the University of Bergen.publishedVersio

Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis

© 2007 - 2018 Frontiers Media S.A. All Rights Reserved. Antimicrobial-resistant microbes are an increasing threat to human health. In cystic fibrosis (CF), airway infections with Pseudomonas aeruginosa remain a key driver of lung damage. With few new antibiotics on the development horizon, alternative therapeutic approaches are needed against antimicrobial-resistant pathogens. Phage therapy, or the use of viruses that infect bacteria, is one proposed novel therapy to treat bacterial infections. However, the airways are complex microenvironments with unique characteristics that may affect the success of novel therapies. Here, three phages of P. aeruginosa (E79, F116, and one novel clinically derived isolate, designated P5) were screened for activity against 21 P. aeruginosa strains isolated from children with CF. Of these, phage E79 showed broad antibacterial activity (91% of tested strains sensitive) and was selected for further assessment. E79 genomic DNA was extracted, sequenced, and confirmed to contain no bacterial pathogenicity genes. High titre phage preparations were then purified using ion-exchange column chromatography and depleted of bacterial endotoxin. Primary airway epithelial cells derived from children with CF (n = 8, age range 0.2-5.5 years, 5 males) or healthy non-CF controls (n = 8, age range 2.5-4.0 years, 4 males) were then exposed to purified phage for 48 h. Levels of inflammatory IL-1β, IL-6, and IL-8 cytokine production were measured in culture supernatant by immunoassays and the extent of cellular apoptosis was measured using a ssDNA kit. Cytokine and apoptosis levels were compared between E79-stimulated and unstimulated controls, and, encouragingly, purified preparations of E79 did not stimulate any significant inflammatory cytokine responses or induce apoptosis in primary epithelial cells derived from children with or without CF. Collectively, this study demonstrates the feasibility of utilizing pre-clinical in vitro culture models to screen therapeutic candidates, and the potential of E79 as a therapeutic phage candidate in CF

The DEEP Groth Strip Survey VI. Spectroscopic, Variability, and X-ray Detection of AGN

We identify active galactic nuclei (AGN) in the Groth-Westphal Survey Strip (GSS) using the independent and complementary selection techniques of optical spectroscopy and photometric variability. We discuss the X-ray properties of these AGN using Chandra/XMM data for this region. From a sample of 576 galaxies with high quality spectra we identify 31 galaxies with AGN signatures. Seven of these have broad emission lines (Type 1 AGNs). We also identify 26 galaxies displaying nuclear variability in HST WFPC2 images of the GSS separated by ~7 years. The primary overlap of the two selected AGN samples is the set of broad-line AGNs, of which 80% appear as variable. Only a few narrow-line AGNs approach the variability threshold. The broad-line AGNs have an average redshift of z~1.1 while the other spectroscopic AGNs have redshifts closer to the mean of the general galaxy population (z~0.7). Eighty percent of the identified broad-line AGNs are detected in X-rays and these are among the most luminous X-ray sources in the GSS. Only one narrow-line AGN is X-ray detected. Of the variable nuclei galaxies within the X-ray survey, 27% are X-ray detected. We find that 1.9+/-0.6% of GSS galaxies to V=24 are broad-line AGNs, 1.4+/-0.5% are narrow-line AGNs, and 4.5+/-1.4% contain variable nuclei. The fraction of spectroscopically identified BLAGNs and NLAGNs at z~1 reveals a marginally significant increase of 1.3+/-0.9% when compared to the local population.Comment: 29 pages, 8 figures, accepted for publication in ApJ

Practitioner\u27s Guide to Technology, Pedagogy, and Content Knowledge (TPACK): Rich Media Cases of Teacher Knowledge

The goal of the TPACK Practitioners Guide is simple--to offer exemplary cases of technology integration efforts that result in curriculum-based student learning in each of the following nine content areas and grade level contexts: Elementary Science, Elementary Math, Elementary Social Studies, Elementary Reading, Middle School Language Arts, Secondary Science, Secondary Math, Secondary Social Studies, and, Secondary English.https://scholarworks.wm.edu/book/1000/thumbnail.jp

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes : A meta-analysis of randomized controlled trials

Aims: To perform a meta-analysis of randomized controlled trials (RCTs), including 6 recently published large-scale cardiovascular outcome trials (CVOTs), to evaluate the risk of pancreatic cancer with incretin-based therapies in patients with type 2 diabetes (T2DM). Materials and Methods: For the period January 1, 2007 to May 1, 2017, the PubMed, Embase, Cochrane Central Register and databases were searched for RCTs in people with T2DM that compared incretin drugs with placebo or other antidiabetic drugs, with treatment and follow-up durations of >= 52 weeks. Two reviewers screened the studies, extracted the data and assessed the risk of bias independently and in duplicate. Results: A total of 33 studies (n = 79971), including the 6 CVOTs, with 87 pancreatic cancer events were identified. Overall, the pancreatic cancer risk was not increased in patients administered incretin drugs compared with controls (Peto odds ratio [OR] 0.67, 95% confidence interval [CI] 0.44-1.02). In the 6 CVOTs, 79 pancreatic cancer events were identified in 55248 participants. Pooled estimates of the 6 CVOTs showed an identical tendency (Peto OR 0.65, 95% CI 0.42-1.01). Notably, in the subgroup of participants who received treatment and follow-up for >= 104 weeks, 84 pancreatic cancer events were identified in 59919 participants, and a lower risk of pancreatic cancer was associated with incretin-based therapies (Peto OR 0.62, 95% CI 0.41-0.95). Conclusions: Treatment with incretin drugs was not associated with an increased risk of pancreatic cancer in people with T2DM. Instead, it might protect against pancreatic malignancy in patients treated for 104 weeks.Peer reviewe